TNBC-Selective VHH Antibody for Cell-Based Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a limitation on effective therapy for triple-negative breast cancer (TNBC), necessitating a method for diagnosing or treating this subtype of breast cancer.
Innovation Solution
Development of a VHH antibody that selectively recognizes TNBC cells compared to HER2-positive and hormone receptor-positive breast cancer cells, utilizing specific amino acid sequences and CDRs to achieve selective binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibodies are used for breast cancer detection, then they can recognize common breast cancer types, but they cannot selectively distinguish TNBC from other breast cancer subtypes
Solution Approach 1:
The patent introduces point mutations at specific positions (K32A, E35A, Q99K, N100K) within the VHH antibody sequence to locally modify the antigen-binding properties. These targeted amino acid substitutions in the framework and CDR regions enhance the antibody's ability to specifically recognize TNBC cells while maintaining stability, thereby achieving selective discrimination of TNBC from other breast cancer subtypes.
2Measurement precision
If VHH antibody sequences are modified to improve TNBC recognition, then selective binding to TNBC is enhanced, but the stability of the antibody may be compromised
Solution Approach 1:
The patent systematically modifies amino acid parameters at specific positions in the VHH sequence (K32A, E35A, Q99K, N100K) to optimize the balance between TNBC recognition selectivity and antibody stability. These parameter changes involve substituting specific amino acids to alter the electrostatic interactions and hydrogen bonding networks, thereby achieving enhanced TNBC binding affinity while preserving the overall structural integrity of the antibody.
Data Source
AI summary
A technique for selectively recognizing TNBC is provided. An antibody against a triple-negative breast cancer cell (TNBC) selectively recognizes a TNBC in comparison to a HER2-positive breast cancer cell and a hormone receptor-positive breast cancer cell.